Skip to content
Search

Latest Stories

Precautions must be stepped up to protect public against new Covid variant, says RPS

The Royal Pharmaceutical Society (RPS) has cautioned that measures to protect people against Covid-19 must be stepped up in the wake of discovery of the new variant, B.1.1.529.

It has urged members of the public to practice ‘hands, face, space and ventilation’ protection measures which have become less used in the last few months.


RPS director of pharmacy Robbie Turner said that though it was too early to conclude about the transmissibility or resistance of the new variant to current vaccines, quick action should be taken to protect the public.

"Each one of us must take the necessary precautions of wearing a mask in higher risk situations, maintaining social distancing wherever possible, ensuring there’s appropriate ventilation indoors when meeting others and washing our hands regularly.”

Encouraging people to take Covid vaccine, he said, it “is still our best defence against this virus”.

He noted that many community pharmacies are providing vaccination service and remain open for long hours in convenient locations.

Turner said: "We must protect each other and the NHS, which is already working at full capacity and beyond. Face coverings should always be worn in healthcare settings including community pharmacies."

Professor Andrew Pollard, director of the Oxford Vaccine Group, said existing vaccines should work against the new strain, but a clearer conclusion can be drawn after more research in the coming weeks.

More For You

Walgreens Boots Alliance acquired by Sycamore in deal

Walgreens Boots Alliancehas entered into “a definitive agreement” to be acquired by Sycamore Partners

Gettyimages

Walgreens Boots Alliance acquired by Sycamore in £18.3 billion deal

Walgreens Boots Alliance(WBA) has entered into “a definitive agreement” to be acquired by Sycamore Partners, a private equity firm specializing in retail, consumer and distribution-related investments.

“The total value of the transaction represents up to $23.7 billion (£18.3 billion),” the company announced late last night (6).

Keep ReadingShow less
Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.

Keep ReadingShow less
PDA calls on GP practices to use funding boost to improve job security for pharmacists

Now, it is time to focus on the community pharmacy contract

gettyimages

PDA urges GP practices to ensure funding boost supports employed pharmacists

The Pharmacists' Defence Association (PDA) has called on GP practicesto ensure that all healthcare professionals they employ, including pharmacists, benefit from the 7.2% funding boost they received under a newly agreed contract.

GP employers are encouraged to improve “job security, pay and conditions” for employees with this increased funding.

Keep ReadingShow less
Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Lawrence Tallon named new MHRA chief executive

Lawrence Tallon

Photo credit: Sciana Network

Lawrence Tallon named new MHRA chief executive

Lawrence Tallon has been appointed as the new chief executive officer of the Medicines and Healthcare products Regulatory Agency (MHRA), effective 1 April 2025.

He will succeed Dame June Raine DBE, who is retiring after leading the agency since 2019.

Keep ReadingShow less